GO
Loading...

AstraZeneca PLC

More

  • China fines GlaxoSmithKline $492M for bribery Friday, 19 Sep 2014 | 4:22 AM ET

    BEIJING— Drug maker GlaxoSmithKline was fined $492 million on Friday for bribing doctors in China, the biggest such penalty ever imposed by a Chinese court. The court sentenced the company's former China manager, Briton Mark Reilly, and four Chinese co-defendants to prison but postponed the sentences for two to four years, suggesting they may never be served.

  • Sept 18- Rite Aid Corp cut its full-year profit forecast for the second time in about three months due to lower margins in its pharmacy business, sending its shares down more than 16 percent.

  • Nektar says FDA clears constipation drug Movantik Tuesday, 16 Sep 2014 | 2:01 PM ET

    British drugmaker AstraZeneca PLC will market the drug, and it has also filed for regulatory approval in the European Union and Canada. The San Francisco company said Movantik will be available to patients in the first half of 2015. AstraZeneca will conduct a study to evaluate the drug's cardiovascular side effects. AstraZeneca stock fell 9 cents to $73.69.

  • Lilly, AstraZeneca team up on Alzheimer's drug Tuesday, 16 Sep 2014 | 10:36 AM ET

    INDIANAPOLIS— Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

  • NEW YORK, Sept 16- U.S. stocks were set to open lower on Tuesday with traders positioning for a Federal Reserve meeting expected to provide clues on the short term direction of U.S. interest rates.

  • US STOCKS-Futures dip ahead of data, Fed eyed Tuesday, 16 Sep 2014 | 7:33 AM ET

    *The Labor Department's producer price index, due at 8:30 a.m. EDT, is expected to have risen 0.1 percent in August, the same as in July.

  • *Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.

  • Weaker healthcare stocks weigh on European equities Tuesday, 2 Sep 2014 | 12:40 PM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- A fall in major healthcare stocks, after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer, pegged back European stock markets on Tuesday. "We wouldn't chase stocks at these levels," said HED Capital head Richard Edwards.

  • BUSINESS-NEWS-SCHEDULE AT 1500 GMT / 11:00 a.m. ET Tuesday, 2 Sep 2014 | 11:02 AM ET

    Dollar General sweetens Family Dollar bid, may go hostile. Dollar General Corp raises its bid for Family Dollar Stores Inc to $9.1 billion, and warns it may turn hostile and appeal directly to shareholders if the new offer is rejected.

  • European equities dip as healthcare stocks weaken Tuesday, 2 Sep 2014 | 10:16 AM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- European shares slipped on Tuesday as major healthcare stocks fell after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer. A 1.8 percent fall at AstraZeneca took the most points off the index.

  • BARCELONA, Sept 2- Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Strict British takeover rules limit what Soriot and other players can say about Pfizer's abortive attempt to buy AstraZeneca and the possibility of a resumption of talks.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Trading volumes light ahead of Labor Day holiday. NEW YORK, Aug 29- U.S. stocks closed out a strong month on a quiet note on Friday, with the S&P 500 posting a modest gain to close at a new record as the latest positive data helped extend a rally that had been briefly threatened by overseas concerns.

  • NEW YORK, Aug 29- U.S. stocks edged higher in a quiet session on Friday as the latest in a string of positive data pushed investors to extend a rally that had been briefly threatened by overseas concerns, although gains were capped ahead of an extended holiday weekend.

  • NEW YORK, Aug 29- U.S. stocks were slightly lower on Friday, with investors finding few reasons to extend a long-running rally, even as the latest economic data joined the trend of better-than-expected reports on the economy.

  • Early movers: BIG, GOOG, S, AVGO, AZN, AAPL & more Friday, 29 Aug 2014 | 7:34 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE).

    Some of the names on the move ahead of the open.

  • NEW YORK, Aug 29- U.S. stock index futures were modestly higher on Friday, suggesting the market's recent upswing was intact and pointing to a fourth straight week of gains for major indexes.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Stock futures hold mild gains amid economic reports Tuesday, 26 Aug 2014 | 9:02 AM ET

    Wall Street was seen opening flat on Tuesday, with Dow futures marginally higher and S&P 500 futures slightly lower.